Oncologic Committee To Meet Nov. 8 On Accelerated Approval Commitments
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee to revisit drugs with postmarketing commitments previously reviewed in 2003 and give advice for conduct of confirmatory studies for sponsors with newly approved drugs.
You may also be interested in...
Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains
FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.
Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains
FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.
MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology
Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.